1. A compound represented by the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof wherein
W is selected from the group consisting of:
(a) \u2014CH2\u2014C(A)\u2550C(B)\u2014CH2\u2014;
\u2003wherein,
A and B are independently selected from the group consisting of:
(i) hydrogen;
(ii) deuterium;
(iii) halogen;
(iv) R1, wherein R1 is selected from the group consisting of:
a. C1-C6 alkyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
b. C2-C6 alkenyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
c. C2-C6 alkynyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
(v) R2, wherein R2 is selected from the group consisting of:
a. aryl;
b. heteroaryl;
c. substituted aryl; and
d. substituted heteroaryl;
(vi) \u2014(C1-C3-alkyl)-M-(C1-C3-alkyl)-R2, wherein M=\u2014O\u2014, \u2014NH\u2014, \u2014N(CH3)\u2014, \u2014NHC(O)\u2014 or \u2014S(O)n\u2014, wherein n=0, 1 or 2, and R2 is as previously defined;
(vii) \u2014(C1-C3-alkyl)-M-R2, wherein M and R2 are as previously defined;
(viii) \u2014C(O)-J-R3, wherein J is absent, O or S, and R3 is H, R1 or R2;
\u2003where R1 and R2 are as previously defined; and
(ix) \u2014C(O)\u2014NR11R12, wherein R11 and R12 are each independently selected from the group consisting of:
a. hydrogen;
b. C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
c. C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
d. C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of: halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
e. R1 and R12 taken together with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain one or more heterofunctions selected from the group consisting of: \u2014O\u2014, \u2014NH\u2014, \u2014N(C1-C6-alkyl)-, \u2014N(R2)\u2014, \u2014S(O)n\u2014, wherein n and R2 are as previously defined;
(b) \u2014CH2\u2014CH(A)-C(B)=CH\u2014, wherein A and B are as previously defined;
(c) \u2014CH2\u2014CH(E)-CH(G)-CH2\u2014;
wherein E and G are independently selected from the group consisting of:
(i) A, wherein A is as previously defined;
(ii) \u2014OH;
(iii) \u2014O\u2014R9, wherein RP is a hydroxy protecting group;
(iv) \u2014O\u2014R9, wherein R9 is R1 or R2, and wherein R1 and R2 are as previously defined;
(v) \u2014S(O)nR9, wherein n and R9 are as previously defined;
(vi) \u2014NHC(O)R3, wherein R3 is as previously defined;
(vii) \u2014NHC(O)NR11R3, wherein R11 and R3 are as previously defined;
(viii) \u2014NHS(O)2R9, wherein R9 is as previously defined;
(ix) \u2014NHR13, wherein R13 is an amino protecting group; and
(x) \u2014NR11R12, wherein R11 and R12 are as previously defined;
(d)
\u2003wherein:
(i) -Q- is selected from the group consisting of: \u2014O\u2014; \u2014O\u2014C(O)\u2014CH(R7)\u2014; \u2014N(R7)\u2014; \u2014O\u2014C(O)\u2014N(R7)\u2014; \u2014O\u2014C(O)\u2014O\u2014; \u2014N(R7)\u2014N\u2550N\u2014; \u2014C(R7)\u2550N\u2014O\u2014; and \u2014CH(R7)\u2014N(R8)\u2014O\u2014; wherein R7 and R9 are independently selected from R3, wherein R3 is as previously defined; or
(ii) -Q- taken together with the two carbon atoms it is attached to is selected from the group consisting of:
a. cycloalkylene;
b. cycloalkenylene; and
c. heterocycloalkylene; and
(e) \u2014CH2\u2014C(R4)(R5)\u2014CH2\u2014CH2\u2014;
wherein R4 and R5 taken together with the carbon atom to which they are attached are selected from the group consisting of:
(i) C\u2550O;
(ii) C(OR1)2, wherein R1 is as previously defined;
(iii) C(SR1)2, wherein R1 is as previously defined;
(iv) C\u2014O(CH2)m2, wherein m is 2 or 3;
(v) C\u2014S(CH2)m2, wherein m is as previously defined,
(vi) C\u2550CHR3, wherein R3 is as previously defined;
(vii) C\u2550N\u2014O\u2014R3, wherein R3 is as previously defined;
(viii) C\u2550NNHR3, wherein R3 is as previously defined;
(ix) C\u2550NNHC(O)R3, wherein R3 is as previously defined;
(x) C\u2550NNHC(O)NR11R3, wherein R11 and R3 are as previously defined;
(xi) C\u2550NNHS(O)2R9, wherein R9 is as previously defined;
(xii) C\u2550NNHR13, wherein R13 is as previously defined; and
(xiii) C\u2550NR9, wherein R9 is as previously defined;
X and Y are:
(a) independently selected from the group consisting of:
(i) hydrogen;
(ii) deuterium;
(iii) \u2014OH;
(iv) \u2014ORP, wherein RP is as previously defined; and
(v) \u2014NR14R15, wherein R14 and R15 are each independently selected from the group consisting of:
a. hydrogen;
b. C1-C12 alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heteroaryl and substituted heteroaryl; and
c. R14 and R15, taken together with the nitrogen atom to which they are attached form a 3 to 10 membered heterocycloalkyl ring optionally substituted with one or more hetero atoms selected from the group consisting of O, S and N; or
(b) taken together with the carbon atom to which they are attached are selected from the group consisting of:
(i) C\u2550O;
(ii) C\u2550NR3, wherein R3 is as previously defined;
(iii) C\u2550NC(O)R3, wherein R3 is as previously defined;
(iv)C\u2550N\u2014OR6, wherein R6 is selected from the group consisting of:
a. hydrogen;
b. \u2014CH2O(CH2)2OCH3;
c. \u2014CH2O(CH2O)nCH3, wherein n is as previously defined;
d. C1-C12 alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heteroaryl and substituted heteroaryl;
e. C3-C12 cycloalkyl;
f. C(O)\u2014C1-C12 alkyl;
g. C(O)\u2014(C3-C12 cycloalkyl);
h. C(O)\u2014R2, wherein R2 is as previously defined; and
i. \u2014Si(Ra)(Rb)(Rc), wherein Ra, Rb and Rc are each independently selected from the group consisting of C1-C12 alkyl, aryl and substituted aryl; and
(v) C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, wherein R16 and R17 taken together with the carbon atom to which they are attached form a C3 to C12 cycloalkyl group or each independently is selected from the group consisting of: hydrogen, and C1-C12 alkyl; and R18 is selected from the group consisting of:
a. hydrogen;
b. \u2014CH2O(CH2)2OCH3;
c. \u2014CH2O(CH2O)nCH3, wherein n is as previously defined;
d. C1-C12 alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heteroaryl and substituted heteroaryl;
e. C3-C12 cycloalkyl; and
f. \u2014Si(Ra)(Rb)(Rc), wherein Ra, Rb and Rc are as previously defined;
L is selected from the group consisting of:
(a) \u2014CH(OH)CH3;
(b) C1-C6 alkyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
(c) C2-C6 alkenyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
(d) C2-C6 alkynyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
K is selected from the group consisting of:
(a) R10, wherein R10 is selected from the group consisting of:
(i) hydrogen;
(ii) \u2014ORP, wherein RP is as previously defined;
(iii) \u2014OR3, wherein R3 is as previously defined;
(iv) \u2014OC(O)R3, wherein R3 is as previously defined;
(v) \u2014OC(O)NR11R3, wherein R11 and R3 are as previously defined; and
(vi) \u2014S(O)nR9, wherein n and R9 are as previously defined; and
(b)
\u2003wherein R3\u2033 is hydrogen or methyl; R4\u2033 is hydrogen or RP, wherein RP is as previously defined; and
Rx is hydrogen or RP, wherein RP is as previously defined.
2. A compound according to claim 1 wherein X and Y taken together with the carbon atom to which they are attached are selected from the group consisting of: C\u2550O, C\u2550NR3, C\u2550N\u2014O\u2014R6, C\u2550N\u2014C(O)R3 and C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, wherein R3, R6, R16, R17 and R18 are as defined in claim 1.
3. A compound according to claim 2 wherein X and Y taken together with the carbon atom to which they are attached are selected from the group consisting of:
C\u2550NC(O)CH3 and C\u2550N\u2014O\u2014CH2\u2014O\u2014CH3.
4. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, Rx and R4\u2033 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
5. A compound according to claim 4 wherein X and Y taken together with the carbon atom to which they are attached are selected from the group consisting of: C\u2550O, C\u2550NR3, C\u2550N\u2014O\u2014R6, C\u2550N\u2014C(O)R3 and C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, wherein R3, R6, R16, R17 and R18 are as defined in claim 1.
6. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
7. A compound according to claim 6 wherein X and Y taken together with the carbon atom to which they are attached are selected from the group consisting of: C\u2550O, C\u2550NR3, C\u2550N\u2014O\u2014R6, C\u2550N\u2014C(O)R3 and C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, wherein R3, R6, R10, R16, R17 and R18 are as defined in claim 1.
8. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, Rx and R4 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof
9. A compound according to claim 8 wherein X and Y taken together with the carbon atom to which they are attached are selected from the group consisting of: C\u2550O, C\u2550NR3, C\u2550N\u2014O\u2014R6, C\u2550N\u2014C(O)R3 and C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, wherein R3, R6, R16, R17 and R18 are as defined in claim 1.
10. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
11. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, Rx and R4 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
12. A compound according to claim 1 represented by the formula:
wherein A, B, X, Y, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
13. A compound according to claim 1 represented by the formula:
wherein Q, X, Y, Rx and R4\u2033 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
14. A compound according to claim 1 represented by the formula:
wherein Q, X, Y, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
15. A compound according to claim 1 represented by the formula:
wherein E, G, X, Y, Rx and R4\u2033 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
16. A compound according to claim 1 represented by the formula:
wherein E, G, X, Y, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
17. A compound according to claim 1 represented by the formula:
wherein X, Y, R4, R5, Rx and R4 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
18. A compound according to claim 1 represented by the formula:
wherein X, Y, R4, R5, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
19. A compound according to claim 1 represented by the formula:
wherein X, Y, R4, R5, Rx and R4\u2033 are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
20. A compound according to claim 1 represented by the formula:
wherein X, Y, R4, R5, R10 and Rx are as defined in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.
21. A compound according to claim 1 selected from the group consisting of:
Compound of Formula (II): A=B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014OH; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (IV): A=3-quinolyl; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014OH; Rx=H and R4\u2033=C(O)CH3;
Compound of Formula (II): A=C(O)OCH3; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014OH; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (II): A=B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (VIII): Q=\u2014C(C6H5)\u2550N\u2014O\u2014; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (VIII): Q=\u2014O\u2014C(O)\u2014O\u2014; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (VIII): Q=\u2014O\u2014; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (VIII): Q=\u2014O\u2014; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=H;
Compound of Formula (II): A=B=H; X and Y taken together with the carbon atom they are attached to=C\u2550NC(O)CH2OCH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (II): A=B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)\u2014CH2OCH3; Rx=H and R4\u2033=H;
Compound of Formula (IV): A=3-quinolyl; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (IV): A=3-quinolyl; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=H;
Compound of Formula (II): A=C(CH\u2550CH\u2014C6H5); B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033=C(O)C6H5;
Compound of Formula (II): A=C(CH\u2550CH\u2014C6H5); B=H; X and Y taken together with the carbon atom they are attached to=C\u2550NC(O)CH3; Rx=H and R4\u2033=H;
Compound of Formula (II): A=C(CH\u2550CH\u2014C6H5); B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014C(O)CH3; Rx=H and R4\u2033C(O)C6H5;
Compound of Formula (II): A=C(CH\u2550CH\u2014C6H5); B=H; X and Y taken together with the carbon atom they are attached to=C\u2550NC(O)CH3; Rx=H and R4\u2033=H;
Compound of Formula (II): A=H; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014Ac; Rx=H and R4\u2033=H;
Compound of Formula (II): A=C(O)\u2014OH; B=H; X and Y taken together with the carbon atom they are attached to=C\u2550N\u2014OH; Rx=H and R4\u2033=H; and
Compound of Compound of Formula (II): A=B=H, X and Y taken together with the carbon atom they are attached to=C\u2550O, Rx=H and R4\u2033=C(O)CH3.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier.
23. A method for controlling a bacterial infection in an animal comprising administering to an animal a therapeutically effective amount of a pharmaceutical composition according to claim 22.
24. A process for preparing a compound of formula:
wherein A, B, and RX are as defined in claim 1, V taken together with the carbon atom it is attached to is selected from the group consisting of: C\u2550O, C\u2550NR3, C\u2550N\u2014O\u2014R6, C\u2550N\u2014C(O)R3 and C\u2550N\u2014O\u2014C(R16)(R17)\u2014O\u2014R18, where R3, R6, R16, R17 and R18 are as defined in claim 1, and R4\u2033 is a hydroxy protecting group;
comprising the step of reacting a compound of the formula:
\u2003wherein R4\u2033, RX and V are as defined previously,
with an alkylating agent of the formula:
\u2003wherein R19 is C1-C6 alkyl and A and B are as defined in claim 1, in an aprotic solvent in the presence of a palladium catalyst at a temperature between room temperature and 80\xb0 C. to produce the claimed compound.
25. A process for preparing a compound of formula:
\u2003wherein R4\u2033 is a hydroxy protecting group and A, B and Rx are as defined in claim 1, the process comprising the steps:
(a) hydrolyzing a compound of formula:
\u2003wherein R4\u2033 is a hydroxy protecting group and A, B, R6 and Rx are as defined in claim 1,
\u2003in a protic solvent optionally with aqueous acid or base to obtain the compound of formula:
\u2003wherein R4.\u2033 A, B and Rx are as defined previously; and
(b) reducing the product of step (a) with a reducing agent to obtain the claimed compound.
26. A process for preparing a compound of formula:
wherein A, B, R3, Rx and R4\u2033 are as defined in claim 1;
the process comprising the step of acylating a compound of formula:
wherein A, B Rx and R4 are as previously defined, with R3C(O)T or (R3C(O))2O, where R3 is as defined in claim 1 and T is a hydroxy group or halogen, under basic conditions using an acylating agent in an aprotic solvent, optionally using an activation agent.
27. A process for preparing a compound of formula:
wherein R4\u2033 is a hydroxy protecting group, and A, B and Rx are as defined in claim 1;
the process comprising the steps:
(a) reacting a compound of the formula:
\u2003wherein R4\u2033 and V are as defined in claim 1 and Rx is as previously defined, with an alkylating agent of the formula:
\u2003wherein R19 is C1-C6 alkyl and A and B are as previously defined, in an aprotic solvent in the presence of a palladium catalyst at a temperature between room temperature and 80\xb0 C. to produce the compound of formula:
\u2003wherein R6 is as defined in claim 1, RP1 is H or RP1 where RP is as defined in claim 1, and R4,\u2033 A, B and Rx, are as defined previously;
(b) reacting the compound from step (a) with a protic solvent optionally with aqueous base followed by reduction with a reducing agent to produce a compound of formula:
\u2003wherein R4,\u2033 A, B, RP1 and Rx are as previously defined;
(c) removing the RP1 protecting group from the compound of step (b) and acylating the resulting hydroxy group with di-tert-butoxycarbonate to produce compound of formula:
\u2003wherein Boc is a tert-butoxycarbonyl group and wherein R4,\u2033 A, B and Rx are as previously defined; and
(d) reacting the compound from step (b) with a palladium catalyst and a phosphorous ligand to obtain the claimed compound.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An integrated system for ensuring the performance and health of a plurality of wire systems, end devices, and processes, said system comprising:
a plurality of signals each representing an output from one of a plurality of end devices;
an output device, said output device adapted to send a test signal to a selected one of said end devices; and
a computer responsive to said plurality of signals, said computer communicating with said output device, said computer programmed to execute a process for verifying wiring system, end device, and process health comprising:
storing a plurality of sampled data in a storage media, said plurality of sampled data corresponding to said plurality of signals;
analyzing said sampled data and producing analysis results, said step of analyzing including performing a static analysis and performing a dynamic response analysis, and said step of analyzing further including performing an analysis of at least one of an amplitude probability density, a power spectral density, and a time domain reflectometry; and
determining a condition of said at least one of said plurality of end devices.
2. The integrated system of claim 1 wherein said process further includes determining whether a corrective action is required by said analysis results.
3. The integrated system of claim 1 wherein said process further includes determining whether a corrective action is required by said analysis results, and if corrective action is required, initiating said corrective action by communicating with said output device.
4. The integrated system of claim 1 wherein said condition includes at least one of a defective sensor, a skewed data distribution, and a cable condition.
5. The integrated system of claim 1 wherein said process further includes calibrating said one of said end devices based on said sampled data if said one of said end devices is able to be calibrated.
6. At least one computer programmed to execute a process for verifying the performance and health of a plurality of wire systems, end devices, and processes, the process comprising:
storing a plurality of sampled data in storage media, said sampled data corresponding to a plurality of signals each representing an output from one of a plurality of end devices;
analyzing said sampled data and producing analysis results, said step of analyzing including performing a dynamic analysis and an analysis for wiring condition; and
determining whether a corrective action is required by said analysis results.
7. The process of claim 6 wherein said step of analyzing further includes performing a static analysis.
8. The process of claim 6 wherein said step of analyzing includes performing at least one analysis selected from a group including an analysis of an amplitude probability density, an analysis of a power spectral density, and an analysis of a time domain reflectometry.
9. The process of claim 6 wherein said corrective action includes at least one of an instrument calibration and an in situ test, and further including the step of initiating said corrective action if determined to be required.
10. The process of claim 6 further including a step of initiating an output of a test signal as part of said analysis of said time domain reflectometry, and said sampled data including a reflection signal for said time domain reflectometry.
11. The process of claim 6 further including a step of screening said sampled data to remove outliers.